A medicinal composition for dissolve thrombus and resisting hemagglutination

A composition and a blood coagulation technology, applied in the field of anticoagulant drugs and thrombolysis, can solve the problems of chemical thrombolysis drugs with large side effects, poor performance of oral thrombolysis products, and unsatisfactory thrombolysis effect, and achieve oral safety, convenience and effectiveness. , Enhance thrombolytic ability, excellent thrombolytic effect

Inactive Publication Date: 2019-01-15
路领群
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Cardiovascular and cerebrovascular diseases are the number one killer of human health. Thrombosis is the main risk factor leading to cardiovascular and cerebrovascular diseases and is the main inducing factor. The existing oral thrombolytic products have poor performance, chemical thrombolytic drugs have large side effects, and thrombolytics are not effective. There are many shortcomings such as thoroughness and great side effects on the body. Various oral bioenzyme thrombolytic products include nattokinase, lumbrokinase, etc., which are very easy to be destroyed by gastric acid and have poor stability, resulting in unsatisfactory thrombolytic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] A kind of thrombus-dissolving and anti-coagulant pharmaceutical composition involved in the present embodiment is calculated by daily dosage of 50-500 units of hirudin, 600-6000 units of lumbrokinase, 2000-20000 units of nattokinase, and 0.5 units of edible gelatin. ~5 grams, 0.1~2 grams of sodium bicarbonate (or other basic compounds) and magnesium element (derived from various magnesium-containing compounds, such as magnesium oxide, light magnesium oxide, active magnesium oxide, magnesium hydroxide, magnesium sulfate, Magnesium lactate, magnesium citrate, etc.) 30-300 mg. The product is packaged in three forms: capsules, tablets or powder pouches. Tablets need to be granulated and dried. The drying temperature must be strictly controlled within 60 degrees to prevent the biological enzyme activity from being destroyed.

Embodiment 2

[0050] A kind of thrombus-dissolving and anticoagulant pharmaceutical composition involved in the present embodiment is calculated by 300 units of hirudin, 2000 units of lumbrokinase, 10000 units of nattokinase, 2.5 grams of edible gelatin, 1 gram and elemental magnesium 150mg composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for dissolving thrombus and anti-coagulation, belonging to the technical field of anti-thrombus and anti-coagulation. 50-500 unit of hirudin, 600-6000 units of lumbrokinase, 2000-20000 unit of nattokinase, 0. 5-5g of edible gelatin, 0. 1-2g of sodium bicarbonate and 30-300mg of magnesium. A Chinese medicine in that form of leech, hirudin, an enzyme extracted from earthworms, based on lumbrokinase and nattokinase, as that biological enzyme protect agent (edible gelatin). The combination of gastric acid neutralizer (sodium bicarbonate) and enzyme accelerator (magnesium element) greatly improves the stability of the effective substance in vivo, improves the speed and efficiency of thrombolysis, has excellent thrombolytic effect, and is verysafe to the body, hardly produces side effects, is safe, convenient and effective for oral administration, and is safe, non-toxic and harmless.

Description

technical field [0001] The invention relates to a thrombus-dissolving and anti-coagulation pharmaceutical composition, which belongs to the technical field of thrombus-dissolving and anti-coagulation medicines. Background technique [0002] Cardiovascular and cerebrovascular diseases are the number one killer of human health. Thrombosis is the main risk factor leading to cardiovascular and cerebrovascular diseases and is the main inducing factor. The existing oral thrombolytic products have poor performance, chemical thrombolytic drugs have large side effects, and thrombolytics are not effective. There are many shortcomings such as thoroughness and large side effects on the body. Various oral bioenzyme thrombolytic products include nattokinase, lumbrokinase, etc., which are very easy to be destroyed by gastric acid and have poor stability, resulting in unsatisfactory thrombolytic effect. Contents of the invention [0003] The object of the present invention is to solve the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/58A61K47/42A61K47/02A61P7/02
CPCA61K38/482A61K38/484A61K38/58A61K47/02A61K47/42A61P7/02C12Y304/21007C12Y304/21062A61K2300/00
Inventor 路领群
Owner 路领群
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap